Cannabidiol - TALENT Biotech

Drug Profile

Cannabidiol - TALENT Biotech

Latest Information Update: 04 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TALENT Biotech
  • Class Analgesics; Antiepileptic drugs; Antipsychotics; Anxiolytics; Cannabinoids; Cyclohexenes; Muscle relaxants; Neuroprotectants; Skin disorder therapies; Small molecules
  • Mechanism of Action Cannabinoid receptor CB1 antagonists; Serotonin 1 receptor agonists; Transient receptor potential channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity No

Highest Development Phases

  • Phase II Graft-versus-host disease

Most Recent Events

  • 07 Sep 2017 Kalytera Therapeutics plans a multiple-dose, phase II trial to evaluate the pharmacokinetics, safety and efficacy of Cannabidiol for the prevention of Graft-versus-host disease following allogeneic haematopoietic cell transplantation, in Israel
  • 02 May 2017 Kalytera plans a registrational, dose-ranging trial via adaptive design for Graft versus host disease
  • 26 Apr 2017 Kalytera Therapeutics has patents pending for the composition of matter and method of use of cannabinoid therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top